Article

Hip Replacement Surgery Boosts Fracture Risk in Patients With Osteoarthritis

Fracture risk in patients with hip osteoarthritis (OA) undergoing a total hip replacement (THR) procedure increases by 25% at 2.5 to 5 years postsurgery. Bisphosphonate use reduces fracture risk in patients in whom there was no fracture before surgery and in those who had a previous osteoporotic fracture and received the treatment in secondary prevention.

Fracture risk in patients with hip osteoarthritis (OA) undergoing a total hip replacement (THR) procedure increases by 25% at 2.5 to 5 years postsurgery. Bisphosphonate use reduces fracture risk in patients in whom there was no fracture before surgery and in those who had a previous osteoporotic fracture and received the treatment in secondary prevention.

Prieto-Alhambra and colleagues conducted a population-based parallel-cohorts study of patients in the UK General Practice Research Database undergoing THR for hip OA. Five controls were identified for each case and matched with patients by age, sex, and practice site. Patients were monitored for up to 5 years. Fracture rates and rate ratios were estimated, and bisphosphonate use was identified among patients undergoing THR.

Fracture rates were higher in patients undergoing THR after surgery and significantly higher at years 2.5 to 5 postsurgery. There was a 44% decrease in fracture risk in bisphosphonate users in whom there was no fracture before surgery and a 52% reduction in those with a previous osteoporotic fracture.

The authors noted that because patients who have undergone THR are at increased risk for fracture, they may need to be properly assessed for fracture risk before or at the time of surgery.

Related Videos
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2025 MJH Life Sciences

All rights reserved.